衰弱与COVID-19 mRNA疫苗抗体反应:社区研究
完全接种后60天内1.4%未检出抗体阳转,衰弱者阳转可能性低于非衰弱者(校正OR 3.75,95%CI 1.04–13.5);中位6个月随访中3.1%出现抗体转阴,衰弱者转阴风险高于非衰弱者(校正OR 3.02,95%CI 1.17–7.33)。总体抗体反应较高,但衰弱是抗体反应受损的独立预测因素。
要点
- 衰弱者接种mRNA疫苗后抗体阳转可能性低于非衰弱者。
- 衰弱者随访期间抗体转阴风险高于非衰弱者。
- 总体抗体反应较高,但衰弱应纳入疫苗研究与预防策略。
核心结论
- 衰弱是COVID-19 mRNA疫苗抗体反应受损的独立预测因素。
- 总体抗体反应在年龄和衰弱分层中均较高。
研究设计与样本
- 比较衰弱状态与完全接种后抗体阳转及后续抗体转阴,采用逻辑回归模型。
主要发现
- 中位年龄67岁(四分位距62–72岁),非衰弱879人(52%)、前衰弱678人(40%)、衰弱120人(7.2%)。
- 完全接种后60天内23人(1.4%)未检出抗体阳转,衰弱者阳转可能性低于非衰弱者,校正OR 3.75(95%CI 1.04–13.5)。
临床怎么用
- 对衰弱老年人接种COVID-19 mRNA疫苗后,应关注其抗体反应可能较弱。
- 在疫苗研究和预防策略中应考虑衰弱状态。
局限性
- 抗体检测不能完整描述疫苗反应。
- 研究为观察性设计,来自单一美国医疗系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined. METHODS: Observational study of adults aged 55 and older from 1 U.S. health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index (eFI) score from their medical record (n = 1 677). Participants' frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models. RESULTS: Of 1 677 older adults with median (interquartile range) age, 67 (62 and 72) years, and frailty status (nonfrail: 879 [52%], prefrail: 678 [40%], and frail: 120 [7.2%]), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than nonfrail individuals, adjusted odds ratio (OR) 3.75, 95% confidence interval (CI; 1.04, 13.5). Seroreversion was detected in 50/1 631 individuals (3.1%) over 6 months of median follow-up antibody testing. Frail individuals were more likely to serorevert than nonfrail individuals, adjusted OR 3.02, 95% CI (1.17, 7.33). CONCLUSION: Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomplete descriptor of vaccine response, the high sensitivity of this antibody combined with health-system data reinforce our conclusions that frailty is an independent predictor of impaired antibody response to the COVID-19 mRNA vaccines. Frailty should be considered in vaccine studies and prevention strategies.
引用
- Semelka CT, DeWitt ME, Callahan KE, et al. Frailty and COVID-19 mRNA Vaccine Antibody Response in the COVID-19 Community Research Partnership. J Gerontol A Biol Sci Med Sci. 2022. PMID: 35446945. doi:10.1093/gerona/glac095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。